Description

Sermorelin + GHRP-6 Blend

Sermorelin + GHRP-6 Blend contains 5mg of Sermorelin and 5mg of GHRP-6, totaling 10mg.

Sermorelin
CAS Number	86168-78-7
Molar Mass	3357.93 g·mol−1
Chemical Formula	C149H246N44O42S
IUPAC Name	L-Tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide

GHRP-6
CAS Number	87616-84-0
Molar Mass	873.032 g·mol−1
Chemical Formula	C46H56N12O6
IUPAC Name	L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-Lysinamide

Introduction

The Sermorelin + GHRP-6 Blend is a research peptide formulation tailored for scientific investigation. Combining the properties of Sermorelin and GHRP-6, this blend is designed to facilitate research into growth-related processes, potential synergies, and the impact on testosterone and brain health.

Key Characteristics

Sermorelin is known for its ability to stimulate growth hormone release, Sermorelin is a vital component contributing to the growth-related focus of this research blend. GHRP-6 is recognized for its growth hormone-releasing properties, GHRP-6 complements Sermorelin, offering researchers a comprehensive tool for studying growth-related processes.

Research Applications

The Sermorelin + GHRP-6 Blend is specifically formulated for researchers exploring growth-related processes, potential synergies between Sermorelin and GHRP-6, and examining the effects on testosterone and brain health.

Research Benefits

Potential for Synergistic Benefit

Researchers are encouraged to investigate the combined effects of Sermorelin and GHRP-6, exploring potential synergies in growth-related processes.

Sermorelin and Testosterone

Studies may focus on understanding the relationship between Sermorelin and testosterone, providing insights into potential hormonal interactions.

GHRP-6 and Brain Health

The blend offers a platform for research into the potential impact of GHRP-6 on brain health, contributing to a deeper understanding of its effects.

Summary

The Sermorelin + GHRP-6 Blend stands as a valuable research tool for scientific exploration into growth-related processes, potential synergies, and the effects on testosterone and brain health. Researchers can leverage this blend to gain insights into the combined effects of Sermorelin and GHRP-6.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Chatelain PG, Sanchez P, Saez JM. Growth hormone and insulin-like growth factor I treatment increase testicular luteinizing hormone receptors and steroidogenic responsiveness of growth hormone deficient dwarf mice. Endocrinology. 1991 Apr;128(4):1857-62. doi: 10.1210/endo-128-4-1857. PMID: 2004605. [Read More].
2. Subirós N, Pérez-Saad HM, Berlanga JA, Aldana L, García-Illera G, Gibson CL, García-Del-Barco D. Assessment of the dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016 Mar;38(3):187-95. doi: 10.1179/1743132815Y.0000000089. Epub 2016 Apr 19. PMID: 26311576. [Read More].